Universe Pharmaceuticals Ownership
| UPC Stock | USD 0.21 0.06 22.22% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 3.6 M | Current Value 3.6 M | Avarage Shares Outstanding 14.6 M | Quarterly Volatility 8.7 M |
Universe |
Universe Stock Ownership Analysis
About 37.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.14. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Universe Pharmaceuticals recorded a loss per share of 49.37. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 18th of November 2024. Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited. Universe Pharmaceuticals is traded on NASDAQ Exchange in the United States. For more information please call Gang Lai at 86 79 6840 3309 or visit https://www.universe-pharmacy.com.Besides selling stocks to institutional investors, Universe Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Universe Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Universe Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Universe Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
About 7.0% of Universe Pharmaceuticals are currently held by insiders. Unlike Universe Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Universe Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Universe Pharmaceuticals' insider trades
Universe Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Universe Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Universe Pharmaceuticals backward and forwards among themselves. Universe Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Universe Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-09-30 | 242.5 K | Mml Investors Services Inc | 2024-09-30 | 234.3 K | Two Sigma Securities, Llc | 2024-09-30 | 90.4 K | Renaissance Technologies Corp | 2024-09-30 | 39.3 K | Quadrature Capital Llp | 2024-09-30 | 24.9 K | Virtu Financial Llc | 2024-09-30 | 16.6 K | Xtx Topco Ltd | 2024-09-30 | 14.8 K | Millennium Management Llc | 2024-09-30 | 13.8 K |
Universe Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Universe Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Universe Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Universe Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
White John V over six months ago Acquisition by White John V of 10050 shares of Universe Pharmaceuticals at 19.1667 subject to Rule 16b-3 | ||
Trippeer Richard A Jr over six months ago Acquisition by Trippeer Richard A Jr of 6200 shares of Universe Pharmaceuticals at 33.48 subject to Rule 16b-3 | ||
Moore Jackson W over six months ago Acquisition by Moore Jackson W of 308212 shares of Universe Pharmaceuticals at 29.22 subject to Rule 16b-3 | ||
Moore Jackson W over six months ago Acquisition by Moore Jackson W of 13100 shares of Universe Pharmaceuticals subject to Rule 16b-3 |
Universe Pharmaceuticals Outstanding Bonds
Universe Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Universe Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Universe bonds can be classified according to their maturity, which is the date when Universe Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Universe Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.82) | Earnings Share (49.37) | Revenue Per Share | Quarterly Revenue Growth (0.30) | Return On Assets |
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Universe Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.